Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Arthritis, Juvenile Rheumatoid
Interventions: Celecoxib, Naproxen; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 31
States / cities: San Diego, California • Hartford, Connecticut • Delray Beach, Florida + 21 more

Conditions: Depression, Coronary Artery Disease (CAD), Acute Coronary Syndrome (ACS)
Interventions: Sertraline (Zoloft), Simvastatin (Zocor); Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Anesthesia
Interventions: One spray CTY-5339-A, One spray CTY-5339-CB, Two sprays CTY-5339-A, One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo); Combination Product · Drug
Lead sponsor: Cetylite Industries; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Drug Overdose, Drug Overdose Accidental
Interventions: BSAFE Intervention, Attention control; Behavioral
Lead sponsor: San Francisco Department of Public Health; Government
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy
Interventions: PF-07295324, PF-07259955; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Depressive Disorder, Major
Interventions: Esketamine, Placebo, Standard of Care; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 18
States / cities: San Diego, California • Farmington, Connecticut • Miami, Florida + 14 more

Conditions: Alzheimer's Disease
Interventions: Semorinemab, Placebo, [18F]GTP1; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 31
States / cities: Garden Grove, California • Los Alamitos, California • Palo Alto, California + 28 more

Conditions: Chronic Subdural Hematoma, Subdural Hematoma
Interventions: Embolization of the Middle Meningeal Artery, Standard of care including possible surgical evacuation of subdural hematoma; Procedure
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Alopecia Universalis (AU), Alopecia Totalis (AT)
Interventions: Vehicle, ATI-50002; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2189265, Sitagliptin, Placebo solution, Placebo tablet, Metformin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 35
States / cities: Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: Treatment-Resistant Depression
Interventions: MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg, Placebo Subcutaneous Injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 3
States / cities: Birmingham, Alabama • Oakland Park, Florida • Tampa, Florida

Conditions: Coagulopathy, Hemorrhage
Interventions: Autologous Spray Dried Plasma; Combination Product
Lead sponsor: Velico Medical; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Cincinnati, Ohio • Milwaukee, Wisconsin • West Bend, Wisconsin

Conditions: Internal Hemorrhoids
Interventions: Anucort-HC, 25 Mg Rectal Suppository, Placebo suppository; Drug
Lead sponsor: G & W Laboratories Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Huntsville, Alabama • Sanford, Florida • Wyoming, Michigan

Conditions: Epilepsy
Interventions: Placebo, Brivaracetam; Other · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 26
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 23 more

Conditions: Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions: Ixo-vec, Aflibercept; Genetic · Drug
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 79
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 65 more

Conditions: Drug Use, Harmful Use
Interventions: Quit Using Drugs Intervention Trial, Health behavior maintenance; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lupus Erythematosus, Systemic
Interventions: Atacicept 75 milligram (mg), Atacicept 150 mg, Placebo; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 30
States / cities: Anniston, Alabama • Birmingham, Alabama • Anaheim, California + 24 more

Conditions: Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration
Interventions: LFG316, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Tucson, Arizona • Torrance, California • Fort Myers, Florida + 4 more

Conditions: Contraceptive Device
Interventions: SILCS and lubricant, SILCS and spermicide; Other
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Norfolk, Virginia

Conditions: Prader-Willi Syndrome
Interventions: Cannabidiol, Placebo; Drug
Lead sponsor: Radius Pharmaceuticals, Inc.; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Tucson, Arizona • San Diego, California • Iowa City, Iowa + 4 more

Conditions: Post-polypectomy Bleeding, Anti-platelet Therapy, Colonoscopy
Interventions: Not listed
Lead sponsor: Dallas VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 715 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Active Dermatomyositis
Interventions: BAF312, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 6
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 3 more

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%, SBI-100 Ophthalmic Emulsion, Placebo; Drug
Lead sponsor: Skye Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Glendale, California • Newport Beach, California • Cranberry Township, Pennsylvania

Conditions: Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Interventions: Enpatoran, Placebo, Standard of care (SoC); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: Upland, California • DeBary, Florida • Fort Lauderdale, Florida + 12 more

Search by objective public record fields.

A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA

A Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease

Experimental Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray in Normal Volunteers

Behavioral Safety and Fentanyl Education: BSAFE

A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955

54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

Dartmouth Middle Meningeal Embolization Trial (DaMMET)

Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)

A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

Ascending Dose Study of FrontlineODP™ Spray Dried Plasma

Safety and Efficacy Study of Anucort HC TM 25mg Rectal Suppositories to Treat Symptomatic Internal Hemorrhoids

A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Preventing Drug Use in Low Income Clinic Populations

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

Postcoital Testing of the SILCS Diaphragm

Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome

Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study

Safety and Efficacy of BAF312 in Dermatomyositis

Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)